Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ankylosing Spondylitis (Bekhterev’s Disease) - Overview
Ankylosing Spondylitis (Bekhterev’s Disease) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Ankylosing Spondylitis (Bekhterev’s Disease) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ankylosing Spondylitis (Bekhterev’s Disease) - Companies Involved in Therapeutics Development
Ankylosing Spondylitis (Bekhterev’s Disease) - Drug Profiles
Ankylosing Spondylitis (Bekhterev’s Disease) - Dormant Projects
Ankylosing Spondylitis (Bekhterev’s Disease) - Discontinued Products
Ankylosing Spondylitis (Bekhterev’s Disease) - Product Development Milestones
Featured News & Press Releases
Aug 17, 2022: NICE Recommends RINVOQ (upadacitinib) as a treatment option for active ankylosing spondylitis (AS) in adults
Jul 27, 2022: Mabpharm announces approval of clinical trial application of CMAB015 by the tiol Medical Products Administration of Chi
Jul 21, 2022: Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz (adalimumab-adaz) high concentration formulation (HCF)
Jul 20, 2022: Health Cada approves AbbVie’s RINVOQ? (upadacitinib) for the treatment of adults with active ankylosing spondylitis
Jun 01, 2022: AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ?) in Patients with Axial Spondyloarthritis at EULAR 2022
May 02, 2022: FDA grants approval for AbbVie’s Rinvoq to treat ankylosing spondylitis
Apr 11, 2022: Celltrion Healthcare announces the availability of Yuflyma, a high-concentration, low-volume, citrate-free, and latex-free Humira (adalimumab) biosimilar in Cada
Jan 20, 2022: Lynk doses first patient in Phase II ankylosing spondylitis drug trial
Dec 28, 2021: Akeso’s IL-17A monoclol antibody (Gumokimab) completion of patient enrollment in phase II clinical trial for the treatment of ankylosing spondylitis
Dec 08, 2021: Xinkanghe XKH004 ankylosing spondylitis phase II clinical trial investigator meeting was successfully held
Oct 07, 2021: AbbVie’s RINVOQ (upadacitinib) met primary and all ranked secondary endpoints in phase 3 study in ankylosing spondylitis
Jun 25, 2021: AbbVie provides update regarding RINVOQ (upadacitinib) in psoriatic arthritis and ankylosing spondylitis in the U.S.
Feb 16, 2021: Sandoz Cada completes its 5th biosimilar launch with new biosimilar Hyrimoz (adalimumab)
Jan 25, 2021: European Commission approves AbbVie’s RINVOQ (Upadacitinib) for the treatment of Psoriatic Arthritis and Ankylosing Spondylitis
Dec 22, 2020: Chi IND application of recombint anti-human IL-17A/F humanized monoclol antibody injection for AS indication is accepted by CDE
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Ankylosing Spondylitis (Bekhterev’s Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

List of Tables

List of Tables
Number of Products under Development for Ankylosing Spondylitis (Bekhterev’s Disease), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by 3SBio Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by AbbVie Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Akeso Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by AstraZeneca Plc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Avesthagen Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Beijing Eastern Biotech Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Bio-Thera Solutions Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Biocad, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Biogen Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Bioviz Technologies Pvt Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by BioXpress Therapeutics SA, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Bristol-Myers Squibb Co, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Celltrion Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Clover Biopharmaceuticals Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by DNX Biopharmaceuticals Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Dyadic International Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Eli Lilly and Co, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Enzene Biosciences Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Foshan Rexie Biotechnology Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by FunPep Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Hualan Biological Engineering Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Iltoo Pharma, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Immunwork Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Izana Bioscience Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Jiangsu Carephar Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by JiangSu Qyuns Therapeutics Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Johnson & Johnson, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Livzon Pharmaceutical Group Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Luye Pharma Group Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Lynk Pharmaceutical Hangzhou Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Mabpharm Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by MoonLake Immunotherapeutics, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Mycenax Biotech Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by NeuClone Pty Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Nimbus Therapeutics LLC, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by North China Pharmaceutical Group New Drug Research and Development Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Novartis AG, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Outlook Therapeutics Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Pharmapraxis, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by PKU V-Ming (Hefei) Biologics Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Sandoz International GmbH, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Shandong Danhong Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Shanghai Junshi Bioscience Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Shanghai Novamab Biopharmaceuticals Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Siam Bioscience Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by SinoCelltech Group Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by siRNAgen Therapeutics Corp, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Suzhou Zelgen Biopharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Tianjin Hemay Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by UCB SA, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Valin Technologies Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Wuhan Institute of Biological Products Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by XinThera Inc, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Dormant Projects, 2022
Ankylosing Spondylitis (Bekhterev’s Disease) - Dormant Projects, 2022 (Contd..1)
Ankylosing Spondylitis (Bekhterev’s Disease) - Dormant Projects, 2022 (Contd..2)
Ankylosing Spondylitis (Bekhterev’s Disease) - Discontinued Products, 2022